CHEOF (Cochlear) Valuation Rank


CHEOF Cochlear Ltd CHEOF
62 GF Score
Price $81.42
GF Value $219.83
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Cochlear Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Cochlear Valuation Rank Related Terms

CHEOF
62GF Score
Cochlear Ltd CHEOF
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cochlear (CHEOF) Overvalued in 2026?

Based on GuruFocus' analysis, Cochlear stock appears to be undervalued. The current stock price of $81.42 is trading 63% below its estimated GF Value™ of $219.83. GuruFocus considers Cochlear to be Significantly Undervalued.

Key valuation signals for CHEOF:

  • Valuation Rank:
  • GF Value™: $219.83 vs. price of $81.42 (63% below fair value)
  • GF Score™: 62/100 with 2 warning signs

No single metric tells the full story. See the CHEOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cochlear Business Description

Address 1 University Avenue, Macquarie University, Sydney, NSW, AUS, 2109
Cochlear is the leading cochlear implant device manufacturer, with around 60% global market share. Developed markets contribute 80% of group revenue, where cochlear implants are the standard of care for children with severe-to-profound hearing loss. The company also actively targets the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remaining 20% of group revenue. Main products include cochlear implants, bone-anchored hearing aids, and associated sound processors. In fiscal 2025, 49% of revenue came from the Americas, 34% from Europe, the Middle East, and Africa, and 18% from the Asia-Pacific segment.
62GF Score

Get the complete analysis for CHEOF

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$81.42
Price
$219.83
GF Value